Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epsolay on Skin Microbiome and Biophysical Properties in Rosacea
NCT05675501Phase 1Completed
- Sponsor
- Sol-Gel Technologies
- Start
- Jun 2020
- Primary completion
- Jul 2021
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of benzoyl peroxide + sulfur in papulopustular rosacea (2 arms), sponsored by Sol-Gel Technologies. Primary endpoints: Change in skin microbiome diversity at 8 weeks, Change in transepidermal water loss at 8 weeks and 3 more. Started Jun 2020; status: completed.
02
Drugs
benzoyl peroxide + sulfur
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on NCT05675501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05675501.